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Summary Anti-tumour effector cells were generated through 4 days culture of normal C57BL/6 splenocytes
in a medium containing concanavalin A supernatant and then fractionated with Dolichos biflorus lectin (DBA)
into DBA+ (agglutinable with DBA) and DBA- (non-agglutinable with DBA) cells. The DBA- cells, infused
intravenously into mice together with B16 melanoma cells, or adoptively transfered into mice 3 days after the
injection of B16 cells, caused a marked decrease in the number of lung nodules, while the DBA + cells exerted
no effect. On the other hand, the DBA + cells exhibited higher cytolytic activity in vitro than the DBA- cells in
short-term 5'Cr-release assays. Then, we analysed the mechanism of the strong anti-tumour activity of DBA-
cells in vivo. We found that DBA- cells showed higher reponse to recombinant interleukin-2 (rlL-2) than
DBA+ cells and proliferated very well with a small amount of IL-2. In addition, DBA- cells adhered more
strongly to lung endothelial cells than DBA+ cells in response to rlL-l or rTNF. Furthermore, DBA- cells
produced larger amounts of macrophage activating factor (MAF) including IFN-'y when cultured with B16
melanoma. Taken together, our results show that DBA- cells are effective in reducing experimental pulmonary
metastases not only by the direct lytic activity but also by the indirect killing activity through the activated
macrophage.
In previous studies, we fractionated splenocytes of X5563
tumour-bearing mice, which had been treated with the super-
natant of mouse splenocytes cultured with concanavalin A
(Con A sup), with Dolichos biflorus lectin (DBA) into DBA +
(agglutinable with DBA) and DBA- (non-agglutinable with
DBA) cells and demonstrated that DBA- cells showed strong
antitumour activity against X5563 in vivo when injected into
mice together with human recombinant interleukin-2 (rIL-2),
despite the fact that DBA' cells showed stronger cytolytic
activity in vitro than DBA- cells (Okada et al., 1986).
Recent studies have shown that murine splenocytes or
human peripheral blood lymphocytes, on incubation in vitro
in the presence of IL-2, acquire the ability to lyse a variety of
fresh syngeneic murine and autologous human tumour cells
in short-term 5'Cr-release assays. These lymphokine-activated
killer (LAK) cells are distinct from natural killer (NK) cells
or classical cytotoxic T-cells, and are lytic toward allogenic
tumour target cells from murine and human sources as well
(Grimm et al., 1982, 1983; Grimm & Rosenberg, 1983;
Rosenstein et al., 1984).
The adoptive transfer of syngeneic LAK cells in conjunc-
tion with the systemic administration of rIL-2 reduced the
number of pulmonary and hepatic metastases from murine
tumours of different histological types (Lafreniere &
Rosenberg, 1985a, b; Mule et al., 1984, 1985, 1986a; Moshe
et al., 1986).
In the present study, we examined the ability of Con A
sup-cultured cells, separated with the use of DBA, to reduce
the number of experimental pulmonary metastases in a
murine model. Then we investigated the mechanism of anti-
tumour activity of DBA- cells in vivo, in terms of the follow-
ing characteristics of the effector cells: (1) the proliferation
rate in response to rIL-2; (2) the lymphokine producing
activity; (3) the binding activity to lung endothelial cells
under inflammatory conditions.
Materials and methods
Mice
Female C57BL/6, BALB/c and DBA/2 mice (7- 12 weeks
old) were used in these experiments. The mice were obtained
from Charles River Japan Inc. (Kanagawa, Japan).
Tumours
The B16 melanoma tumour line used was of C57BL/6 origin.
B16 tumour cells (I x 105) were injected into the tail veins of
C57BL/6 mice. After 21-23 days, the animals were killed,
their lungs harvested and then the pulmonary nodules
counted. Complete enumeration of the experimental meta-
stases was possible because they comprised black nodules on
the surface of the lungs. This tumour line was maintained in
RPMI-1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS; MA Bioproducts, Walkers-
ville, MD, USA), 20 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulphonic acid (HEPES), 2 mM glutamine (Wako Pure
Chemical Co., Tokyo, Japan), penicillin (100 U-1'; Sigma
Chemical Co., St Louis, MO, USA) and streptomycin
(100 fig ml- '; Sigma Chemical Co.). Cultured cells were
harvested by treatment with Ca2 + /Mg2+-free Hank's
balanced salt solution containing 0.05% trypsin and 0.02%
disodium EDTA at 37'C for 5 min. RPMI-1640 medium
containing 10% FCS was added to stop the reaction and
then the cells were washed twice with RPMI-1640 medium.
Cells were resuspended in the appropriate buffer at the
appropriate concentration and used for inoculation.
Con A sup
Spleen cells from female BALB/c mice (8- 12 weeks old) were
treated with modified Gey's BSS, to lyse erythrocytes, and
then cultured at 37°C under 5% CO2 in air for 22-24 h in
RPMI-1640 medium supplemented with 5 x 10-5 M 2-
mercaptoethanol (Sigma), 4 mM glutamine, 1 mM sodium
pyruvate, 20 mM HEPES (pH 7.2), 1% non-essential amino
acids (GIBCO), penicillin (100 U ml-') and streptomycin
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(100pgmlm') (complete medium) containing Con A
(2.5 g ml1') and 2.5% FCS. Then the supernatant was
filtered through a membrane filter (pore size, 0.2tsm; Toyo
Roshi, Tokyo, Japan), and stored at - 20C until use. The
supernatant (Con A sup) thus prepared was generally used
for the cell cultures.
Assayfor IL-2 activity
The IL-2 activity present in the Con A sup prepared by the
method described above was determined in a standard micro-
assay method based upon the IL-2 dependent proliferation of
CTLL-2 cells (Gillis et al., 1978), which were cultured in
flat-bottomed microplate wells in complete medium (200jsl).
Each well contained 104 CTLL cells together with log 2
dilution (ranging from 3% to 50% by volume) of the Con A
sup. As a positive control, rIL-2 (Takeda Chemical Industries
Ltd, Osaka, Japan) was added to the cultures. The activity of
the rIL-2 preparation was defined as I U per 27 ng by the
supplier. After a 24 h incubation (37°C in a humidified atmo-
sphere of 5% CO2 in air) the microplate wells were pulsed
with 0.5pCi of 3H-TdR (15 Ci mmol-l; New England
Nuclear, Boston, MA, USA). Cultures were harvested 6 h
later onto glass fibre filter strips and 3H-TdR incorporation
was determined with a liquid scintillation counter (LCS-700,
Aloka, Tokyo, Japan).
Generation ofcytotoxic effector cells
The spleens were removed from female C57BL/6 mice and
then teased into a single cell suspension in RPMI-1640
medium. The cells were then centrifuged and the pellet
resuspended in modified Gey's BSS for 3-4 min at room
temperature, to lyse erythrocytes. The cells were then washed
three times and cultured at 37°C under 5% CO2 in air in
24-well plates (no. 3424; Costar, Cambridge, MA, USA) at a
concentration of 2 x 106 cells ml-' with 10% Con A sup. On
day 3, the culture supernatant was removed, and the cells
were harvested, washed and then recultured in the same
medium containing 10% Con A sup. Two days later, the cells
were harvested and separated with the DBA lectin (EY
Laboratory, San Mateo, CA, USA) before i.v. injection or in
vitro cytotoxicity assays.
Separation ofcytotoxic effector cells through the use ofthe
DBA
The Con A-sup-cultured cytotoxic effector cells were
separated through rosetting with DBA-coupled sheep red
blood cells (SRBC) followed by Ficoll-Urografin density
gradient centrifugation as previously described (Okada et al.,
1986). The DBA+ (rosette-forming cells with DBA-SRBC)
and DBA- (non-rosette-forming cells with DBA-SRBC) cells
were treated with modified Gey's BSS, to lyse SRBC, and
then washed with a solution of 50 mM N-acetyl-D-galacto-
samine, a haptenic sugar for the DBA lectin.
5'Cr-release ofcytotoxicity assay
The 4 h chromium release assay was used in this study.
Varying numbers of effector cells (100 slI) and 104 viable
51Cr-labelled tumour target cells were plated in the wells of
96-well round bottomed microplated (Sumitomo, Osaka,
Japan) in a total volume of 200 LI. The plates were cen-
trifuged at 100g for I min and then incubated at 37°C under
5% CO2 in air for 4 h. Then the plates were centrifuged
again at 250g for 5 min, and the supernatants (100p1) were
harvested and subjected to radioactivity counting with a
gamma-counter (ARC-500 auto well gamma system; Aloka,
Tokyo, Japan). The spontaneous release was determined by
incubating 5'Cr-labelled target cells alone, and the maximum
release was determined after lysing the target cells in 0.4 N
NaOH. The percentage of specific 51Cr release was calculated
according to the following formula:
% of specific 5'Cr release =
experimental release (c.p.m.) - spontaneous release (c.p.m.) 100
maximum release (c.p.m.) - spontaneous release (c.p.m.)
The spontaneous release was less than 10% B16 of the
maximum release in all experiments.
Adoptive immunotherapy models
C57BL/6 mice were given i.v. injections of 1 x 105 melanoma
cells in 200gil of RPMI-1640 medium. Cytotoxic effector cells
were suspended at 4-5 x 106 cells in 200;l of RPMI-1640
medium and then injected into the tail vein together with the
tumour or 3 days after the tumour cell injection. On days
21-23 after the tumour cell injection, the mice were killed for
enumeration of metastatic pulmonary nodules. The nodules
were counted in a blind fashion, i.e. without knowledge of
the treatment. Lungs with metastases too numerous to count
upon autopsy were assigned an arbitrary value of 280, since
we were able to count reliably only up to about 280 meta-
stases per lung.
Phenotyping ofcytotoxic effector cells
DBA-separated or unseparated cells (1 x 106) were prein-
cubated on ice for 1 h (first incubation) with 200 il of
monoclonal biotinyl anti-LytI.2 (final dilution, 1/50) or
monoclonal biotinyl anti-Lyt2.2 (final dilution, 1/50) (Becton
Dickinson, Mountainview, CA, USA) in PBS containing
0.1% NaN3 and 0.1% bovine serum albumin (PBS-NaN3-
BSA), and then they were washed twice and treated with
200gil of fluorescein isothiocyanate (FITC)-conjugated avidin
(final dilution, 1/100) (Vector Laboratories, Burlingame, CA,
USA) on ice for 30 min (second incubation).
When staining cells for analysis of L3T4 antigens, the first
incubation was performed with monoclonal anti-L3T4 (final
dilution, 1/10; Becton) and the second with FITC-conjugated
anti-rat kappa (final dilution, 1/50; Becton).
When staining cells for analysis of the affinity of the DBA
lectin, the first incubation was performed with biotinyl DBA
(final dilution, 15gg ml-'; Vector) for 30 min, and the
second with FITC-conjugated avidin (final dilution 1/100;
Vector Lab.).
In the case of staining cells for analysis of asialo GM,
(AGMI), the first incubation was performed with anti-AGM,
(final dilution, 1/250; Wako Chemical Co., Osaka, Japan)
and the second with FITC-goat anti-rabbit Ig (IgA + IgG
+ IgM) (final dilution, 1/100; Cappel, West Chester, PA,
USA).
We examined the expression of T cell receptor on effector
cells by staining them with an anti-T3 monoclonal antibody
145-2C11 (Leo et al., 1987) (final dilution, 1/20) for the first
incubation, and with FITC-goat anti-hamster IgG (final dilu-
tion, 1/100; EY Laboratory, San Mateo, CA, USA) for the
second. The expression of NKI. on effector cells was
examined by staining them with the supernatant of anti-
NKl.1-producing PK136 hybridoma (Koo & Peppard, 1984)
(final dilution, 1/10) for the first incubation, and with FITC
goat anti-mouse IgG (Fc fragment specific, final dilution,
1/50; Cappel) for the second.
Staining of cells for analysis for Thyl.2 was performed by
first incubating the cells on ice for 1 h with FITC-conjugated
anti-mouse Thyl.2 (final dilution, 1/100; Bio-Yeda, Rehovot,
Israel), and then, each lot of cells was analysed using a cell
sorter (FCS-1; Japan Spectroscopic Co. Ltd, Tokyo, Japan)
after washing three times with PBS-NaN3-BSA.
Binding to endothelial cells (EC)
EC monolayer adhesion assay (Damle et al., 1987; Cavender
et al., 1987a, b) was performed as follows. Briefly, to a
monolayer of rat lung endothelial cells established by Naka-
jima et al. (1987) in a 96-well flat bottomed plate was added
various doses of rIL-l or rTNFa (200gl per well). After 4 h
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twice, and 5'Cr-labelled DBA-separated cells (4 x 105 per
200 jsl per well) were added. After 1 h incubation (37°C, 5%
C02) the plate was washed three times with a warm medium
to remove non-adherent cells, and 1% Triton X-100 (200ILI
per well) was added. Then the plate was incubated for 10 min
at room temperature. The supernatant (100 Jl per well) was
harvested and assayed for radioactivity with a gamma-
counter (ARC-500 auto well gamma system; Aloka, Tokyo,
Japan). The percentage of the effector cells which bound to
EC was calculated with the following formula:
% T-EC binding =
c.p.m. 0.1 ml lysate
A hA)
c.p.m. in original lymphocyte suspension
Macrophage activatingfactor (MAF) sample
DBA-separated cells (2 x I0 ml-') were cultured with the
B16 melanoma (1 x 105ml-') in a 24-well plate (Costar
no. 3424, Cambridge, MA, USA) in complete medium in-
cluding rIL-2 (0.2 Uml- ). The supernatant was harvested
after 3 days, and stored at - 20'C until assaying for MAF
activity.
Assayfor macrophage activatingfactor activityfor
cytotoxicity (MAF-C activity)
MAF-C activity was assayed essentially by the method of
Higuchi et al. (1987). Briefly, peritoneal exudate cells (PEC)
were obtained from DBA/2 mice 3 days after intraperitoneal
injection of proteose peptone. These PEC (1 x IO' per 100 tl
per well) were plated in a 96-well microplate (Sumitomo,
Osaka, Japan) in RPMI-1640 medium including 10% FCS.
After 2 h incubation (37°C, 5% CO2 in air), the supernatant
was removed, and the MAF sample was added. When the
effect of anti-IFN-y was examined, anti-IFN-i (1/100 rabbit
anti-mouse IFN-y having activity of neutralising
106 U IFN ml-'; Toray Industries Inc., Tokyo, Japan) was
added to the sample. The plate was then incubated for 24 h
(37'C, 5% CO2 in air) before the addition of 3H-TdR
prelabelled P815 cells (104 cells per 200 LLl per well). After
48 h incubation (37°C, 5% CO2 in air), the supernatant
(1001A per well) was harvested and 3H-TdR release was
determined with a scintillation counter. Control release was
determined by incubating 3H-TdR-labelled target cells alone,
and the total count was determined with target cells dissolved
with 1% sodium dodecyl sulphate. The percentage of MAF-
C activity was determined with the following formula.
MAF-C activity (%) =
release in test sample - release in control sample
total count - release in control sample x 100
Results
In vitro cytolytic activity ofDBA-separated effector cells
Since we previously demonstrated that alloreactive CTL
(Yamazaki et al., 1983) and Con A sup-cultured splenocytes
from X5563 tumour-bearing C3H/HeN mice (Okada et al.,
1986) could be enriched in the cell fraction having affinity for
DBA (DBA+ cells), when examined in vitro against X5563
cells in a 4 h 51Cr release assay, we investigated whether or
not Con A sup-cultured splenocytes from normal mice were
enriched in the DBA+fraction in the present study.
To induce cytotoxic effector cells, we used normal
C57BL/6 mouse spleen cells expanded in vitro in a Con A
sup-containing medium. The IL-2 activity present in 10%
(v/v) Con A sup was about 0.2 U ml-' when determined in a
standard microassay using the IL-2 dependent CTL line,
CTLL-2. Splenocytes were cultured for 4 days in the presence
of 10% Con A sup (v/v) and then separated into DBA+ and
DBA- fractions by means of rosette formation using DBA
coupled SRBC. The distribution into the DBA+ and DBA-
fractions was 29.6±2.4% and 70.4± 2.4%, respectively
(mean ± s.e. for seven experiments). To confirm that DBA +
cells were highly enriched in the DBA+ fraction, separated
and unseparated cells were incubated with the biotinyl-DBA
followed by incubation with FITC-avidin, and then the
stained cells (104 cells per sample) were analysed by flow
cytometry. As shown in Table I, DBA+ and DBA- cells
were highly enriched in the DBA+ and DBA- fractions,
respectively.
The cytolytic activity of these cells was determined by the
standard 4-h 5"Cr-release assay. As shown in Figure la, the
DBA+ cells showed stronger cytolytic activity against the
B16 melanoma than the DBA- cells in vitro (E/T = 25;
Student's t test, P<0.01). We also assessed the cytolytic
activity of Con A sup-cultured splenocytes from B16 tumour-
bearing C57BL/6 mice against B16 melanoma cells in vitro.
Viable B16 tumour cells (1 x 106 per mouse) were inoculated
subcutaneously into the backs of C57BL/6 mice. Seven days
later, splenocytes were prepared from these mice and cultured
for 4 days in the same manner. They were separated with the
DBA and then separated cells were tested for lytic activity
against B16 cells. As shown in Figure lb the DBA+ cells
also exhibited stronger cytolytic activity than the DBA- cells
in this case (E/T= 25; Student's t test, P<0.01).
We then examined in vitro cytolytic activity of Con A
sup-cultured splenocytes from normal mice against NK sen-
sitive target cells, YAC-1 and NK resistant target cells, P815
and EL-4. As shown in Figure 2, the DBA+ cells also
showed significantly stronger cytolytic activity than the
DBA- cells in these cases (E/T= 15; Student's t test,
P<0.00l).
In vivo anti-tumour activity ofDBA-separated cells
To evaluate the anti-tumour efficacy of the DBA-separated
cells in vivo, DBA-separated cells (4 x 106) were intravenously
injected into C57BL/6 mice together with B16 cells (1 x 105)
injection (Winn assay). Figure 3a shows the number ofexper-
imental pulmonary metastases determined for each group, in
a blind fashion. The infusion of DBA- cells caused a marked
decrease in the number of lung metastases detectable on day
21, compared with that in mice given DBA+ cells (Student's
t test, P<0.01), or unseparated cells (Student's t test,
P<0.01) or without treatment (Student's t test, P<0.001).
Since DBA- cells showed significantly stronger anti-tumour
effect than DBA+ cells in the Winn assays, then we inves-
tigated the effect of adoptively transferred DBA-separated
cells on B16 tumour nodules in lungs that had already under-
gone micro-metastasis. B16 cells (1 x I05) were intravenously
injected into mice, and 3 days later, DBA-separated cells
(5 x 106) were i.v. transferred. On day 23 after the tumour
cells injection, the number of experimental pulmonary meta-
stases was determined. Figure 3b shows that the adoptive
immunotherapy for established 3-day pulmonary B16 meta-
stases with DBA- cells resulted in a significant reduction in
the number of pulmonary metastatic nodules compared with
the transfer of unseparated or DBA+ cells (Student's t test,
P<0.001). Entirely similar results to those in Figure 3b were
obtained in three independent experiments.
It was demonstrated by Mazumder and Rosenberg (1984)
that injection of LAK cells (1 x 108) could significantly
decrease the number of experimental pulmonary B16
melanoma metastases in mice injected with 2 x 105 B16 cells
Table I Surface phenotypes of DBA-separated cellsa
Cells DBA Thy1.2 2C1I L3T4 Lytl.2 Lyt2.2 AGM, NKI.J
DBA + 90.4 98.3 63.6 40.4 41.5 92.6 79.1 9.1
DBA- 11.5 96.6 72.5 66.0 36.3 86.3 90.4 12.2
Unseparated 27.2 96.1 67.8 n.t. 40.6 91.7 n.t.b 10.8
Valuesare % positivecells.aDBA-separatedcellswereanalysed forthe
expression of surface markers by the flow cytometry. bn.t., not tested.244 T. OKADA et al.
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Figure 2 Cytolytic activity of DBA-separated cells against B16
melanoma (a), YAC-I cells (b), P815 cells (c) and EL-4 cells (d).
The effector cells are the same as Figure la. The cytolytic activity
against each target of DBA+ (@), DBA- (0) and unseparated
(0) cells was examined by the 4 h 5"Cr-release assay. Points,
means for triplicate experiments; bars, s.e.
3 days before the injection of LAK cells, but in the present
study, a much lower number of DBA- effector cells was
found to be sufficient to decrease the number of lung meta-
stases. On the other hand, DBA+ or unseparated cells were
ineffective on adoptive transfer under our experimental con-
ditions.
We obtained the same results for another mouse experi-
mental pulmonary metastasis model; DBA-separated BALB/c
effector cells against NL-17 cells (M. Takano, T. Okada and
T. Osawa, unpublished results) which are a highly metastatic
cell line established from colon adenocarcinoma 26 cells
(Tsuruo et al., 1983).
62 125 25 50 100
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Figure I Cytolytic activity of DBA-separated cells against B16
melanoma cells. Spleen cells from normal C57BL/6 mice were
separated with the DBA lectin after culturing for 4 days in the
presence of 10% (v/v) Con A sup. a, The cytolytic activity
against B16 cells of DBA+ (0), DBA- (0) and unseparated
(0) cells was examined by means of the 4 h 5'Cr-release assay.
Points, means for triplicate experiments; bars, s.e. b, Cytolytic
activity of DBA-separated spleen cells from B16-bearing mice
cultured with Con A sup. B16 cells (106) were subcutaneously
inoculated into the backs of C57BL/6 mice, and 7 days later, the
spleen cells were cultured for 4 days in the presence of 10% (v/v)
Con A sup. These cells were separated into DBA+ (0), DBA-
(0) and unseparated (0) cells, and then examined by means of
the 4 h 5'Cr-release assay. Points, means for triplicate
experiments; bars, s.e.
Phenotypes ofDBA-separated cells
We then determined the surface phenotypes of the DBA-
separated cells. As shown in Table I, most of the DBA+,
DBA- and unseparated cells were highly Thyl.2+. Although
both separated populations (DBA+ and DBA-) were found
to express the L3T4, Lytl.2 and Lyt 2.2 antigens (Table I
and Figure 4), the DBA- fraction contained more L3T4
positive cells than the DBA+ fraction, and the DBA+ frac-
tion consisted of the cells which are a little more positive in
Lyt 1 and Lyt 2 antigens than the DBA- fraction. Both
DBA + and DBA- cells were AGM, +, and these cell popula-
tions contained NK 1.1 + cells. As for the T cell receptor,
both DBA+ and DBA- cells were 2CIll.
Growth rate ofDBA-separated cells in the presence ofIL-2
To examine the reason why DBA- cells, despite their low
cytolytic activity in vitro, are markedly effective in vivo, we
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Binding to endothelial cells ofblood vessel under inflammatory
condition
Infiltration of leukocytes into inflammation sites, such as
tumour metastasis sites, is related to their ability to bind to
endothelial cells of blood vessels under inflammatory condi-
tion. The binding is well known to be regulated by cytokines
such as IL-1 and IFN (Cavender et al., 1987a, b). In vitro
study showed that the pretreatment of endothelial cells with
rIL-1 or rTNF augments their adhesion to lymphocytes or
IL-2 cultured lymphocytes (Damle et al., 1987; Cavender et
al., 1987a, b), and the lymphocyte-binding reached a plateau
at the concentration of I U ml-' of IL-1 (Pober et al., 1986)
or TNF (Cavender et al., 1987b). We tested the rate of the
adhesion of the DBA-separated cells to the endothelial cells
of blood vessels in rat lung after treatment of the endothelial
cells with various doses (0-5 U ml-') of rIL-l or rTNFa.
Since mouse lung endothelial cells were not available, rat
lung endothelial cells kindly donated by Dr M. Nakajima
(MD Anderson Hospital, Houston, TX, USA) were used in
this study. As shown in Figure 6, rIL-1 or rTNFa increased
the adhesion of DBA- cells to endothelial cells while these
lymphokines had no effect on the adhesion of DBA+ cells to
endothelial cells. At the site of the tumour metastases, the
inflammatory lymphokines such as IL-1 or TNF may be
secreted. These results indicate that DBA- cells have an
ability to attach to endothelial cells under the influence of
IL-I or TNF, and they can infiltrate advantegeously into the
tumour metastasis sites. However, similar studies on mouse
lung endothelial cells are still necessary, because there is a
possibilty that cell surface adhesion molecules are different
between mouse and rate endothelial cells.
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Figure 3 a, DBA-separated cells (4 x 106) were injected i.v. into
mice together with B16 cells (I x 105). After 21 days, the mice
were killed and then the number of lung nodules was determined.
b, DBA-separated cells (5 x 106) were injected i.v. into mice that
had been injected 3 days previously with B16 cells (I x 105).
Twenty-three days after the tumour cell injection, the number of
lung metastases was determined.
first examined the response of separated cells to rIL-2. As
shown in Figure 5, DBA- cells were more responsive to
rIL-2 than DBA + cells. These results were quite reproducible
in several independent experiments. Since there seems to be
very little IL-2 in vivo, the high responsiveness of DBA- cells
to IL-2 even in very low concentrations of the factor may be
very advantageous for the cells to proliferate in vivo.
Indirect anti-tumour effect through the elaboration of
lymphokines
Furthermore, since there is a possibilty that DBA- cells act
indirectly through activation of other types of cells by secre-
tion of certain lymphokines, experiments were performed to
find out whether DBA-separated cells secrete the macrophage
activating factor (MAF). DBA-separated or unseparated cells
were cultured with the B16 melanoma in the presence of
rIL-2 for several days. Then the supernatants were tested for
MAF activity. MAF activity was estimated by the induction
of cytolytic activity of proteose peptone-induced macro-
phages (Mqp) against P815 cells. The culture medium used in
these experiments contained polymyxin B to block the effect
of contaminating LPS, if any. As shown in Figure 7, DBA-
cells produced a large amount of MAF when cultured with
the B16 melanoma in the presence of rIL-2 for 3 days. On
the other hand, DBA + or unseparated cells produced only a
detectable level of MAF. In the absence of the B16
melanoma, neither DBA+ nor DBA- cells released MAF,
and no MAF was produced from B16 cells alone under these
cultures conditions. If rIL-2 was not added to the culture
medium, all the effector cells died in 2 days and no MAF was
secreted. These results suggested that DBA- cells were
stimulated by the B16 melanoma in the presence of rIL-2 and
secreted MAF in the culture medium. The production of
MAF was detectable on day 2 and reached a peak on day 3.
After 4 or 5 days, the viability of effector cells decreased and
no MAF activity was detected.
We then examined characteristics of the MAF activity in
DBA- supernatant. As shown in Figure 8, neither LPS nor
murine rIFN-y showed MAF activity by themselves, but
showed MAF activity synergistically. This effect was blocked
by anti-IFN-' antibody. When anti-IFN-y was added to
DBA- sup, MAF activity was almost completely diminished.
These results show that MAF activity in DBA- sup is mainly
mediated by IFN--y, and suggest the possibility that DBA-
cells secrete IFN-y in vivo and the activated M.p thus induced
may also contribute to the anti-tumour activity. However,
direct determinations of IFN-y in the supernatants of DBA-
separated and unseparated cell populations are necessary to
verify this assumption. Furthermore, cytotoxic activity of
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Figure 4 DBA-separated cells were incubated with either monoclonal anti-L3T4, biotinyl-anti-Lytl or biotinyl-anti-Lyt2 antibody,
followed by incubation with FITC-anti-rat kappa (for L3T4) or with FITC-avidin (for Lyt and Lyt 2), and then the stained cells
were analysed.
alveolar macrophages isolated from DBA- cells treated mice
should be examined to confirm the participation of alveolar
macrophages in the suppression of experimental pulmonary
metastasis of tumour cells in DBA- cells treated mice. These
are the next targets of our research.
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Figure 5 IL-2 dependent proliferation of DBA-separated cells.
DBA-separated cells were cultured with different concentrations
of rIL-2. After 24 h, cells were pulsed 'H-TdR (0.5pCi per well)
for 5 h. Points, means for triplicate experiments; bars, s.e. (-)
DBA- cells; (0) DBA+ cells.
Discussion
In this study, the DBA- cells separated from Con A-sup-
cultured mouse splenocytes were found to show high
inhibitory activity toward experimental metastasis when
injected together with B16 tumour cells (Figure 3a) and also
when adoptively transferred 3 days later after inoculation of
the tumour cells (Figure 3b). Furthermore, the cell number
that was sufficient for reducing the number of metastatic lung
nodules was markedly less than that employed for the
therapy involving LAK cells by other investigators. On the
other hand, DBA+ cells showed stronger cytolytic activity in
vitro than DBA- cells (Figure 1), but they showed much
weaker activity in vivo (Figure 3).
The dissociation of the cells responsible for the in vitro
cytolytic effect and the in vivo anti-tumour effect, respectively,
was also demonstrated by other investigators. Mule et al.
(1986b) reported that, in combination with the systemic
administration of rIL-2, LAK cells which had been treated
with anti-Thyl and complement, and which were not cytolytic
in vitro assays, remained as effective as untreated cytolytic
LAK cells upon adoptive transfer in reducing the number of
established pulmonary metastases. Shu et al. (1987) also
showed that although spleen cells, which had been sensitised
in vitro with viable tumour cells and IL-2, from normal
C57BL/6 mice did not exhibit anti-tumour activity in vivo,
they displayed non-specific LAK-like cytotoxic activity in
vitro. They therefore concluded that it is unlikely that the in
vitro cytotoxic activity was directly related to the in vivo
anti-tumour effect.
We investigated some properties of DBA-separated cells in
order to examine the reasons why DBA- cells, despite their
low cytolytic activity in vitro, are much more effective than
DBA+ cells in vivo. For the proliferation response to IL-2,
DBA- cells were demonstrated to be much more responsive
to rIL-2 than DBA + cells (Figure 5). Many investigators
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Figure 7 Activity of macrophage activating factor released in
culture supernatants of DBA-separated cells after stimulation
with B16 cells. DBA-separate cells (2 x lI0 ml-') were incubated
with B16 (I x iO5ml-') in the absence or the presence of rlL-2
(0.2 U ml-') for 3 days. In all experiments polymyxin B
(251tgml-') was added to block the effect ofcontaminating LPS,
if any. Each supernatant was harvested and tested for the MAF
activity. MAF activity was assayed for the induction of cytolytic
activity of proteose peptone-induced PEC against 3H-TdR-
labelled P815 cells and % cytolysis of target cells was calculated
as described in Materials and methods. ( ) DBA+ cells;
(ml) DBA- cells; ( ) unseparated cells; (liii) culture
sup of B16 cells alone.
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Figure 6 Effect of rIL-l or rTNFax on effector-endothelial cell
binding. The monolayer of endothelial cells were treated with
rIL-l or rTNFoa for 4 h, and I h binding of endothelial cells to
5'Cr-labelled DBA-separated cells were measured as described in
Materials and methods. (0) DBA- cells; (0) DBA+ cells.
tried to attack tumour cells with LAK or CTL in combina-
tion with the injection of rIL-2 (Chou & Shu, 1987; Chou et
al., 1988). Since IL-2 is liable to be metabolised and excreted
quickly in vivo, administration of a relatively large amount of
IL-2 is necessary to ensure the in vivo effect of the factor and
this may result in serious side-effects. In this context, the fact
that DBA- cells can proliferate with less IL-2 than DBA+
cells may also explain the greater anti-tumour efficacy of
DBA- cells in vivo, because only a little amount of
endogenous IL-2 is actually available in vivo.
At the site of the inflammation, such as the tissue where
tumour cells are growing, the inflammatory lymphokines are
released. So we examined the adhesion rate of DBA-
separated cells to rat lung endothelial cells (EC) in the
presence of the inflammatory lymphokines such as IL-1 and
TNF. The binding of DBA- cells to rat lung EC was
augmented by the pretreament of EC with rIL-I or rTNFax in
dose-dependent manner (Figure 6). However, the binding of
DBA + cells to EC was not enhanced by this treatment.
These results suggest that DBA- cells effectively bind to the
lung EC in situ of tumour tissue where the inflammatory
lymphokines are released, then infiltrate into the tumour site
and attack the tumour cells.
Since the anti-tumour activity of activated M.p in vivo is
well known (Higuchi et al., 1988), we tested the DBA-
separated cells for their ability to generate M<p activating
factor (MAF). It was found that DBA- cells secreted Mqp
activating factor when cultured with B16 cells (Figure 7), and
this MAF activity mainly depended upon IFN-' (Figure 8).
Although DBA+ cells could also lyse B16 cells and pro-
liferated in the presence of IL-2 in vitro, the supernatant of
DBA+ cells showed only a detectable level of MAF-activity.
These results suggest that DBA- cells can induce activated
Mp in vivo and in addition to the direct cytotoxicity of
DBA- cells, the activated M(p thus induced may contribute
greatly to the anti-tumour activity of DBA- cells in vivo.
Considering the fact that the unseparated cells include about
70% of DBA- cells, but the supernatant of the unseparated
cells shows very low level of the Mp activating activity, there
is a possibility that DBA+ cells produce an inhibitor of MTp
activation.
There is another possibility that DBA- cells can more
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Figure 8 Effect of anti-IFN-y on MAF activity of DBA- sup.
Murine rIFN-y (20 U ml-), LPS (0.1 jig ml-') was added to the
assay medium of MAF activity. Anti-IFN-y (having activity of
neutralising i04 U IFN) was added to DBA- sup (3 days culture
supernatant of DBA - cells with B16 melanoma in the medium
containing 0.2 U ml-' rlL.2) and the MAF activity was assayed
and % cytolysis was calculated by the same method as in Figure
7.
easily localise in situ in tumour tissue. Work is now in
progress in our laboratory to determine the localisation of
DBA+ and DBA- cells which are injected i.v. into B16-
bearing mice.
As for the expression of Thyl antigens, both DBA+ and
DBA- cells in the present study were found to be highly
Thyl + and CD3 positive. Furthermore, both cell populations
were also AGMI + (Table I). Presumably, the majority of our
DBA- effector cells derive from T cells, but NK cells are also
present in this cell population. Yang et al. (1986) reported
that LAK effector cells are clearly Thyl.2+ but Kalland et
al. (1987) and Mule et al. (1987) showed that LAK cells are
heterogenous at both the effector and precursor levels, and a
major part of the LAK activity can be ascribed to IL-2-
activated cells expressing surface markers associated with NK
cells.
In conclusion, DBA- cells can exert the great anti-tumour
efficacy in vivo because of the ability of activate Mgp, high
response to rIL-2, and high binding rate to EC under the
influence of inflammatory lymphokines. Since it was shown
in this study that in vivo anti-tumour activity may have good
correlation with the ability of activating Mgp rather than in
vitro cytolytic activity, further studies on this point in other
tumour models are necessary and now under investigation in
our laboratory.
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